Samsung BioLogics Archives | Be Korea-savvy
Samsung Biologics Offers Up to 100 Million KRW in Total Compensation for New Hires

Samsung Biologics Offers Up to 100 Million KRW in Total Compensation for New Hires

SEOUL, Jan. 31 (Korea Bizwire) –Samsung Biologics has disclosed that the total compensation package for its employees, including wages and benefits, can reach up to 100 million KRW annually for first-year employees. On January 31, it was revealed that Samsung Biologics had shared a “Total Compensation Statement” with its employees for the first time, detailing [...]

Samsung Biologics selects Rapid Micro Biosystems’ Growth Direct® platform to automate critical microbiology quality control testing

Samsung Biologics selects Rapid Micro Biosystems’ Growth Direct® platform to automate critical microbiology quality control testing

Companies share commitment to innovating quality control processes to meet biomanufacturing challenges such as scale, data integrity and accelerating time to market LOWELL, Mass., Jan. 04, 2024 (Korea Bizwire) – Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and [...]

Samsung Biologics Inks US$390.9 mln Manufacturing Deal with Novartis

Samsung Biologics Inks US$390.9 mln Manufacturing Deal with Novartis

SEOUL, July 10 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Monday it has signed a US$390.9 million deal with Novartis Pharma AG to manufacture the Switzerland-based pharmaceutical firm’s products. It is the final contract for an investment letter of intent announced in June last year, in which [...]

Samsung Biologics Seals US$1.08 bln Manufacturing Deals with Pfizer

Samsung Biologics Seals US$1.08 bln Manufacturing Deals with Pfizer

SEOUL, July 4 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Monday it has sealed a combined US$1.08 billion partnership contracts with U.S. pharmaceutical giant Pfizer so far this year. The Korean company said it signed a new contract with Pfizer, a follow-up to the bilateral deal set [...]

Samsung Biologics Inks US$411.3 mln Manufacturing Deal with Pfizer

Samsung Biologics Inks US$411.3 mln Manufacturing Deal with Pfizer

SEOUL, June 8 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Thursday it has signed a US$411.3 million contract with Pfizer to manufacture the U.S. pharmaceutical firm’s products. Under the deal with Pfizer, Samsung Biologics will manufacture Pfizer’s multi-product biosimilar portfolio, including oncology, inflammation and immunotherapy, at its [...]

Samsung’s De Facto Leader Lee Attends Opening Ceremony of Samsung Biologics’ Fourth Plant

Samsung’s De Facto Leader Lee Attends Opening Ceremony of Samsung Biologics’ Fourth Plant

SEOUL, Oct. 11 (Korea Bizwire) — Samsung Group’s de facto leader Lee Jae-yong on Tuesday attended the opening ceremony of the fourth plant of Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, in a sign of the group’s dedication to nurture biopharmaceuticals as one of its next growth drivers. The plant, which [...]

Samsung Biologics Tentatively Agrees to Work with AstraZeneca on Contract Manufacturing

Samsung Biologics Tentatively Agrees to Work with AstraZeneca on Contract Manufacturing

SEOUL, Aug. 12 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Friday it has tentatively agreed to work with multinational pharmaceutical company AstraZeneca on biopharmaceutical contract manufacturing. The company said in a regulatory filing that it signed a letter of intent on the cooperation in a deal valued [...]